Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia
Public ClinicalTrials.gov record NCT00813826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia
Study identification
- NCT ID
- NCT00813826
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Solace Pharmaceuticals
- Industry
- Enrollment
- 204 participants
Conditions and interventions
Conditions
Interventions
- SLC022 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2008
- Primary completion
- Sep 30, 2009
- Completion
- Oct 31, 2009
- Last update posted
- Jul 29, 2009
2009
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Sierra Vista | Arizona | 85635 | — |
| Not listed | Mission Viejo | California | 92691 | — |
| Not listed | Orlando | Florida | 32806 | — |
| Not listed | Plantation | Florida | 33324 | — |
| Not listed | Marietta | Georgia | 30060 | — |
| Not listed | Oak Brook | Illinois | 60523 | — |
| Not listed | Shreveport | Louisiana | 71030 | — |
| Not listed | Brockton | Massachusetts | 20301 | — |
| Not listed | Omaha | Nebraska | 68134 | — |
| Not listed | Rochester | New York | 14618 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Kettering | Ohio | 45429 | — |
| Not listed | Altoona | Pennsylvania | 16602 | — |
| Not listed | Philadelphia | Pennsylvania | 19139 | — |
| Not listed | West Reading | Pennsylvania | 19611 | — |
| Not listed | Dallas | Texas | 75230 | — |
| Not listed | Houston | Texas | 77074 | — |
| Not listed | San Antonio | Texas | 78229 | — |
| Not listed | Midvale | Utah | 84047 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00813826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2009 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00813826 live on ClinicalTrials.gov.